FDA GMP Initiative Shifts Warning Letter Review Back To Agency Centers
Executive Summary
The Center for Drug Evaluation & Research will begin reviewing GMP warning letters March 1 as part of an FDA initiative to create a risk-based approach to pharmaceutical manufacturing
You may also be interested in...
Hamburg Offers Warning Letter "Close-Out" In Plan To Speed Enforcement
FDA Commissioner Margaret Hamburg is including a carrot for industry - a warning letter close-out process - in a multi-stick initiative to strengthen the agency's enforcement program
Hamburg Offers Warning Letter "Close-Out" In Plan To Speed Enforcement
FDA Commissioner Margaret Hamburg is including a carrot for industry - a warning letter close-out process - in a multi-stick initiative to strengthen the agency's enforcement program
Hamburg Offers "Close Out" Carrot To Firms In Plan To Accelerate Enforcement
FDA enforcement initiative eliminates requirement for all warning letters to be reviewed by Office of Chief Counsel.